Cleared Traditional

K070645 - SERADYN QMS TOPIRAMATE

K070645 is an FDA 510(k) clearance for SERADYN QMS TOPIRAMATE, manufactured by Seradyn, Inc.. The device is a Class 2 Toxicology device with product code NWM cleared through the Traditional 510(k) pathway after a 70-day FDA review.

K070645 · Seradyn, Inc. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 2007
Decision
70d
Days
Class 2
Risk

K070645 is an FDA 510(k) clearance for the SERADYN QMS TOPIRAMATE. Classified as Immunoassay, Anti-seizure Drug (product code NWM), Class II - Special Controls.

Submitted by Seradyn, Inc. (Indianapolis, US). The FDA issued a Cleared decision on May 17, 2007 after a review of 70 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3350 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Seradyn, Inc. devices

FDA 510(k) Submission Details - K070645

510(k) Number K070645 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 08, 2007
Decision Date May 17, 2007
Days to Decision 70 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
17d faster than avg
Panel avg: 87d · This submission: 70d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

NWM Device Classification - Class 2, Special Controls

Product Code NWM Immunoassay, Anti-seizure Drug
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3350
Definition To Aid In Management Of Patients Treated With Anti-seizure Drug.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - NWM Immunoassay, Anti-seizure Drug

Devices cleared under the same product code (NWM) and FDA review panel - the closest regulatory comparables to K070645.
ARK Lacosamide Assay
K201089 · ARK Diagnostics, Inc. · Aug 2021
ARK ZONISAMIDE ASSAY, ARK ZONISAMIDE CALIBRATOR, AND ARK ZONISAMIDE CONTRO, MODELS 5022-0001-00, 5022-0002-00, 5022-0003
K091884 · ARK Diagnostics, Inc. · Dec 2009
TOPIRAMATE ASSAY, ARK TOPIRAMATE CALIBRATOR AND ARK TOPIRAMATE CONTROL, MODELS 5015-0001-000, 5015-0002-00, 5015-0003-00
K083799 · ARK Diagnostics, Inc. · Apr 2009
QMS ZONISAMIDE REAGENTS, CALIBRATORS AND CONTROLS
K051211 · Seradyn, Inc. · Nov 2005